Keywords: زوتارولیموس; Drug-eluting stent; Zotarolimus; Sirolimus; Paclitaxel
مقالات ISI زوتارولیموس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: زوتارولیموس; Pirfenidone (Pub Chem CID: 40632); Rapamycin (Pub Chem CID: 5284616); Zotarolimus (Pub Chem CID: 23375907); Everolimus (Pub Chem CID: 6442177); Paclitaxel (Pub Chem CID: 441276); Pirfenidone; Zotarolimus; Everolimus; Rapamycin;
Everolimus- versus zotarolimus-eluting stent following percutaneous coronary chronic total occlusion intervention
Keywords: زوتارولیموس; Coronary artery disease; Drug-eluting stents; Everolimus; Prognosis; Zotarolimus;
First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter
Keywords: زوتارولیموس; drug-eluting stent(s); percutaneous coronary intervention; reference vessel diameter; Resolute Onyx; restenosis; stent(s); zotarolimus; DES; drug-eluting stent(s); MACE; major adverse cardiac event(s); MI; myocardial infarction; PCI; percutaneous coronary
Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease
Keywords: زوتارولیموس; biolimus; drug-eluting; polymer; randomized clinical trial; stent; zotarolimus; DES; drug-eluting stent(s); MACE; major adverse cardiac event(s); MI; myocardial infarction; PCI; percutaneous coronary intervention; ST; stent thrombosis; TLR; target lesion
Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial
Keywords: زوتارولیموس; drug-eluting stent(s); long-term follow-up; probucol; randomized controlled trial; sirolimus; zotarolimus; CI; confidence interval; CK; creatine kinase; DES; drug-eluting stent(s); HR; hazard ratio; MI; myocardial infarction; ULN; upper limit of normal;
Stent Selection and Antiplatelet Therapy Duration
Keywords: زوتارولیموس; drug-eluting stent(s); stent(s); thrombosis; zotarolimus;
Everolimus-Eluting Xience V/Promus Versus Zotarolimus-Eluting Resolute Stents in Patients With Diabetes Mellitus
Keywords: زوتارولیموس; diabetes mellitus; drug-eluting stent; everolimus; percutaneous coronary intervention; zotarolimus; CI; confidence interval; DES; drug-eluting stent(s); DM; diabetes mellitus; EES; everolimus-eluting stent(s); HR; hazard ratio; MI; myocardial infarction;
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: Final results of the ZoMaxx II trial
Keywords: زوتارولیموس; Zotarolimus; Drug-eluting stents; Percutaneous coronary intervention; Restenosis;
Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: A meta-analysis of randomized trials
Keywords: زوتارولیموس; Zotarolimus; Drug-eluting stents; Percutaneous coronary interventionZotarolimus; Stent actif; Angioplastie coronaire percutanéeCI, confidence interval; DES, drug-eluting stent(s); MACE, major adverse cardiovascular events; OR, odds ratio; PCI, percutaneou
The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study
Keywords: زوتارولیموس; Coronary artery disease; Drug-eluting stents; Zotarolimus; Japanese population
A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries : The ZoMaxx I Trial
Keywords: زوتارولیموس; drug-eluting stent; stent; zotarolimus; restenosis; coronary artery diseaseCK, creatine kinase; DES, drug-eluting stents; IVUS, intravascular ultrasound; MACE, major adverse cardiovascular events; MLD, minimum lumen diameter; PC, phosphorylcholine; TLR, t
Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: Application to active pharmaceutical ingredient process development
Keywords: زوتارولیموس; Drug-eluting stent; Zotarolimus; ABT-578; Rapamycin; Sirolimus; RP-HPLC-UV-MS; NP-HPLC-UV-MS; Process impurities; API process analytical development; Impurities tracking and mapping; HPLC impurity profile
Análisis y caracterÃsticas de los stents farmacoactivos disponibles en la actualidad. Futuros desarrollos
Keywords: زوتارولیموس; Stent recubierto; PolÃmeros; Sirolimus; Paclitaxel; Everolimus; Zotarolimus; Biolimus A-9; Drug-eluting stents; Polymers; Sirolimus; Paclitaxel; Everolimus; Zotarolimus; Biolimus A9; CE; Comunidad Europea; EuroPCR; Euro Paris Course on Revascularization;
Zotarolimus (ABT-578) eluting stents
Keywords: زوتارولیموس; Restenosis; Zotarolimus; Coronary stenting; Coronary artery disease